Leukocyte Adhesion Deficiency Type 1 Overview
Learn About Leukocyte Adhesion Deficiency Type 1
Leukocyte adhesion deficiency type 1 is a disorder that causes the immune system to malfunction, resulting in a form of immunodeficiency. Immunodeficiencies are conditions in which the immune system is not able to protect the body effectively from foreign invaders such as viruses, bacteria, and fungi. Starting from birth, people with leukocyte adhesion deficiency type 1 develop serious bacterial and fungal infections.
Mutations in the ITGB2 gene cause leukocyte adhesion deficiency type 1. This gene provides instructions for making one part (the β2 subunit) of at least four different proteins known as β2 integrins. Integrins that contain the β2 subunit are found embedded in the membrane that surrounds white blood cells (leukocytes). These integrins help leukocytes gather at sites of infection or injury, where they contribute to the immune response. β2 integrins recognize signs of inflammation and attach (bind) to proteins called ligands on the lining of blood vessels. This binding leads to linkage (adhesion) of the leukocyte to the blood vessel wall. Signaling through the β2 integrins triggers the transport of the attached leukocyte across the blood vessel wall to the site of infection or injury.
Leukocyte adhesion deficiency type 1 is estimated to occur in 1 per million people worldwide. At least 300 cases of this condition have been reported in the scientific literature.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Elena Almarza practices in Madrid, Spain. Ms. Almarza is rated as an Elite expert by MediFind in the treatment of Leukocyte Adhesion Deficiency Type 1. Her top areas of expertise are Leukocyte Adhesion Deficiency Type 1, Osteopetrosis, Fanconi Anemia, and Congenital Aplastic Anemia.
Juan Bueren practices in Madrid, Spain. Mr. Bueren is rated as an Elite expert by MediFind in the treatment of Leukocyte Adhesion Deficiency Type 1. His top areas of expertise are Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, Leukocyte Adhesion Deficiency Type 1, and Splenectomy.
Manisha Madkaikar practices in Mumbai, India. Ms. Madkaikar is rated as an Elite expert by MediFind in the treatment of Leukocyte Adhesion Deficiency Type 1. Her top areas of expertise are Leukocyte Adhesion Deficiency Type 1, Primary Immunodeficiency (PID), Chronic Granulomatous Disease, and Severe Combined Immunodeficiency (SCID).
Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...
Summary: This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
Published Date: April 01, 2014
Published By: National Institutes of Health